Cargando…

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

PURPOSE: We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung cancers (NSCLC). PATIENTS AND METHODS: In the global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RET-altere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subbiah, Vivek, Gainor, Justin F., Oxnard, Geoffrey R., Tan, Daniel S.W., Owen, Dwight H., Cho, Byoung Chul, Loong, Herbert H., McCoach, Caroline E., Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y., Kherani, Jennifer F., Huang, Xin, Kang, Suhyun, Drilon, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447251/ https://www.ncbi.nlm.nih.gov/pubmed/34088726 http://dx.doi.org/10.1158/1078-0432.CCR-21-0800

Ejemplares similares

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
por: Drilon, Alexander, et al.
Publicado: (2023)

External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
por: Rolfo, C., et al.
Publicado: (2022)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study
por: Zheng, Xiangqian, et al.
Publicado: (2022)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial
por: Cheng, Ying, et al.
Publicado: (2023)

Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
por: Stinchcombe, Thomas E.
Publicado: (2023)

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
por: Lu, Shun, et al.
Publicado: (2022)

Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report
por: Wu, Lin, et al.
Publicado: (2023)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial
por: Lu, Shun, et al.
Publicado: (2023)

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
por: Velazquez, Ana I., et al.
Publicado: (2020)

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
por: Illini, Oliver, et al.
Publicado: (2021)

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
por: Goldman, Jonathan W., et al.
Publicado: (2023)

Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
por: Arora, Aakriti, et al.
Publicado: (2023)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
por: Toda, Soji, et al.
Publicado: (2023)

Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer
por: Huang, Yan, et al.
Publicado: (2023)

Using Time-Varying Covariates in Multilevel Growth Models
por: McCoach, D. Betsy, et al.
Publicado: (2010)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
por: Leite, Caio Abner, et al.
Publicado: (2023)

Correction to: Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_todmbn8fv7np9s7epmd48nsmgs